SEARCH

Current Edition

Aristea Therapeutics

How Involved Should Biopharma CEOs Be In Outsourcing Activities?

When outsourcing drug development and manufacturing, how involved should the CEOs of emerging biopharma be in the requisite day-to-day activities and processes? Louis Garguilo interviews …

Continue Reading →
alvogen

Prestige Biopharma and Alvogen Announce License and Supply Agreement to Commercialize Prestige´s Trastuzumab Biosimilar (Hervelous™) in Central and Eastern Europe Singapore

Prestige BioPharma and Alvogen today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization …

Continue Reading →
Alpha

Alpha Biopharma announces series A financing

 AZD3759, AlphaBio’s lead product, is a next-generation small molecule tyrosine kinase inhibitor (TKI). It is specifically designed to treat epidermal growth factor receptor (EGFR) mutation …

Continue Reading →
biopharma

Wize Pharma signs distribution agreement in China for LO2A

HPGC is a division of Harbin Pharmaceutical Group Co. Ltd., one of China’s largest healthcare companies with 20,000 employees and assets worth $2.9 billion. Wize …

Continue Reading →
Astellas

Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst

The $62 billion Takeda-Shire deal surprised everyone—and worries some—as Takeda is borrowing an enormous $31 billion to help pay for the purchase. Does it refresh the …

Continue Reading →
biopharma group
A-D

Biopharma Group

The Biopharma Group comprises of Biopharma Process Systems (BPS), Biopharma Technologies Ltd (BTL), Biopharma Technology LLC (USA) and Biopharma Technologies France (BTF). Equipment Sales & Service Division: BPS …

Continue Reading →
ambition

8,000 biopharma job opportunities if Ireland has the ambition

Ireland is at the forefront of the biologics trend that is transforming the traditional pharma and biopharma industries. Up to 8,000 jobs are available between …

Continue Reading →
biopharma

For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory

In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of the Memorial Sloan Kettering Cancer Center discuss the …

Continue Reading →
biopharma

Chinese biopharma firm to create 400 jobs in Dundalk

WuXi Biologics will invest €325m in company’s first site outside of China A major Chinese biopharmaceutical company is to create 400 jobs with a €325 …

Continue Reading →